The Brazilian health regulatory agency, Anvisa, has initiated the seizure of tirzepatide manufactured by El Elyon de Manipulação Ltda., which lacks proper sanitary registration and authorization for its production. The action, taken on September 13, 2023, prohibits the sale, distribution, import, and any promotion of the medication within the country. This step reflects Anvisa's commitment to ensuring that pharmaceuticals meet critical safety and efficacy standards before reaching consumers.

The decision arose after it was discovered that the tirzepatide being marketed was sold without having undergone the necessary validation to receive a sanitary registration in Brazil. The lack of authorization from Anvisa indicates that El Elyon failed to comply with mandatory processes that ensure the quality and safety of the medications they produce. The agency's intervention highlights significant regulatory measures aimed at protecting public health and maintaining the integrity of the pharmaceutical market in Brazil.

In attempts to gain insight into the company’s response, reporters reached out to El Elyon; however, as of the time of publication, there was no response from the company. This incident underlines the importance of regulatory oversight in the pharmaceutical industry and serves as a reminder for consumers to be cautious about the legitimacy of marketed medications, particularly those that lack proper regulatory approval.